-In maximizing global access and revenues, biopharmaceutical firms need strategic market access insights that extend beyond just the US and European markets;
- Japan is the second biggest market for patented pharmaceuticals in the world after the US. Value Genome has deep expertise on Japan reimbursement pricing, including knowledge of the complex pricing rules and processes, government policy trends related to drug reimbursement, extensive experience estimating reimbursement price potential and developing strategy to maximize reimbursement. We are your best partner for understanding and succeeding with reimbursement price listing in Japan.
- Affordability remains the number one barrier to access to innovative medicines in the emerging markets in Asia, Latin America, and Africa and the Middle East. Value Genome has firsthand experience in developing programs to maximize access to innovative medicines while optimizing revenue streams with win-win solutions. Researching and designing optimal patient access programs, tiered pricing by income, and other potential access solutions are part of Value Genome’s forte.”
Value Genome consultants are here to partner and assist your team in developing a strong pricing, reimbursement, and access strategy to ensure reimbursement listing and access for patients. Our goal is to help innovative biopharmaceutical firms in optimizing the financial return whether it’s providing product pricing valuation for a licensing or acquisition deal or assisting firms in their US and global product launches.